Unit for Functional Cancer Genomics
Our laboratories are located in building NA second floor of the Vetmeduni Vienna (Institute of Animal Breeding and Genetics). The Richard Moriggl (RM) group is a team of approximately ten personnel, including MSc, PhD students, postdoctoral fellows and biomedical research assistants. In addition personal, administrative grant and secretarial support is available through university infrastructure.
The group is embedded into the Institute of Genetics and Animal Breeding, also located in building NA. The group has vast expertise in establishing and analyzing mouse models in cancer research, with particular know-how on JAK-STAT pathway analysis.
Our facilities are well equipped and staffed for histopathology support or genetic manipulation of primary cells, like viral transduction or xenotransplantation. Daily routine cancer research analysis and examination of core cancer pathways is a central theme. Moreover, next generation sequencing technologies with bioinformatic evaluations came lately into focus of modern cancer research and these collaborative tasks are performed in national networking initiatives.
Our lab is an established centre of excellence in comparative genetics and pathology and analysis of transgenic cancer mouse models. We provide equipment for digital image quantification and state-of-the art diagnostics of core cancer pathways, where we also explore new cancer therapies in animal models.
The research within the group of RM is basic cancer research with translational direction. We do comparative medicine and we make translational models for an emerging need to serve as test systems of genetic findings, which emanate from cancer genomic landscape studies or which serve as a basis for basic and translational cancer research questions.
The group of RM is focused on the JAK-STAT core cancer pathway. The main focus of the group is hematopoietic cancer with a focus on myeloproliverative neoplasm, T cell leukemia and lymphoma formation. Furthermore, studies of metabolism, melanoma, sarcoma, colon and liver carcinoma projects were followed. Molecular mechanisms of transcription factors and kinase actions are analyzed to gain insights into mechanisms of action to control cellular proliferation/survival, PI3K-AKT activation or metabolic cancer cell control in context of tumor cell establishment and progression. Moreover, the group is involved in new targeted therapy developments and establishes test systems for translational cancer research.
Head
Univ.-Prof. Dipl.-Ing. Dr.rer.nat. Richard Moriggl
T +43 1 25077-5622
E-Mail to
Richard Moriggl